Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV mRNA vaccine (Afrigen Biologics)
- Development stage
- Preclinical
- Lead developer
- Afrigen Biologics and Vaccines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
The RSV mRNA vaccine is an investigational messenger RNA-based vaccine candidate being developed by Afrigen Biologics, a South African biotechnology firm acting as the central hub for the WHO and Medicines Patent Pool (MPP) mRNA Technology Transfer Programme. The vaccine is designed to protect against Respiratory Syncytial Virus (RSV) by utilizing mRNA platform technology to encode viral antigens. Upon administration, the vaccine instructs host cells to synthesize these antigens, thereby eliciting a robust adaptive immune response characterized by the production of neutralizing antibodies and T-cell activation. This program is part of a strategic effort to build regional vaccine manufacturing capacity and address the global burden of RSV, particularly in infants and the elderly.
- Other names
- Afrigen RSV mRNA vaccine
02
Targets
RSV G (Respiratory syncytial virus attachment glycoprotein)
Beyond the preview
Go deeper on RSV mRNA vaccine (Afrigen Biologics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV mRNA vaccine (Afrigen Biologics).